New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors
- 1 September 2010
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 39 (3) , 615-628
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- An Analysis of Trends and Growth Factor Receptor Expression of GI Carcinoid TumorsJournal of Gastrointestinal Surgery, 2009
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124Journal of Clinical Oncology, 2009
- Investigational drugs for neuroendocrine tumoursExpert Opinion on Investigational Drugs, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine TumorsJNCI: Journal of the National Cancer Institute, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut OriginNeuroendocrinology, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Microsatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumorsCancer, 2005
- A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndromeCancer, 1991